Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
4093-35-0
Molecular formula
C14H22BrN3O2
Molecular weight
344.25 g/mol
Drug class
Substituted benzamide antiemetic and prokineticdopamine D2-receptor antagonist
Mechanism of action
Antagonises dopamine D2 receptors in the chemoreceptor trigger zone and gastrointestinal tract, reducing emetic signalling and facilitating upper gastrointestinal motility. Experimental data also report 5-HT4-receptor agonist effects in isolated human atrial tissue; their clinical relevance to its GI use is not established.
Indications / reported uses
Nausea and vomiting
Functional dyspepsia and selected upper gastrointestinal motility disorders in countries where bromopride is authorised; approved indications and formulations vary by jurisdiction
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Bromopride PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bromopride Permitted Daily Exposure (PDE) report (the Bromopride PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bromopride Occupational Exposure Limit (OEL) report (the Bromopride OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.